<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82398">
  <stage>Registered</stage>
  <submitdate>8/11/2007</submitdate>
  <approvaldate>16/11/2007</approvaldate>
  <actrnumber>ACTRN12607000588493</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of Tafenoquine for the Post-Exposure Prophylaxis of Vivax Malaria (Southwest Pacific Type) in Non-Immune Australian Soldiers</studytitle>
    <scientifictitle>Comparison of three different dose regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.</scientifictitle>
    <utrn />
    <trialacronym>TQ049</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Comparison of different tafenoquine regimens for tolerability and efficacy of malaria prevention.
Tafenoquine doses of 400mg once daily, 200mg twice daily and 200mg once daily were given to volunteers orally for 3 days prior to departure from a malarious area.</interventions>
    <comparator>Tafenoquine vs Primaquine control. Primaquine was given orally at a dose of 7.5mg three times daily for 14 days as comparator.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary efficacy parameter was the proportion of subjects with confirmed parasitemia during the 12-month follow-up period</outcome>
      <timepoint>Follow up to 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to parasitaemia</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability</outcome>
      <timepoint>Clinical interview at day 3.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biochemical safety and pharmacokinetic analysis</outcome>
      <timepoint>Blood sampling at day 0 and day 3</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Glucose-6-Phosphate Dehydrogenase (G6PD) normal,
Healthy adults</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Pregnant females or females unwilling to use contraception for 30 days following completion of dosing,
G6PD deficiency,
Taking any other investigational drug within 30 days of last dose,
unwilling or unable to give blood.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Volunteers assigned a unique alpha-numeric identifying code after informed consent obtained.
Allocation was conducted by the Principal Investigator or senior co-investigator on site. As it was an open/unblinded trial there was no concealment of allocation involved. Once allocation was completed the files were held at a central administrative site.</concealment>
    <sequence>At the beginning of each recruiting day a coin was tossed to determine which drug the initial entry would take then the remainder of volunteers were allocated drug according to a predetermined ratio</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/02/1999</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress>Biometrics and Data Sciences,
Harlow</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>GlaxoSmithKline</fundingname>
      <fundingaddress>Biometrics and Data Sciences,
Harlow</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Department of Defence</fundingname>
      <fundingaddress>Canberra ACT 2600</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Department of Defence</sponsorname>
      <sponsoraddress>Canberra ACT 2600</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Assessment of various tafenoquine dose regimens to determine the most effective dose for post exposure prophylaxis of P.vivax malaria in the Southwest Pacific</summary>
    <trialwebsite />
    <publication>Nasveld P, Kitchener S, Edstein M, Rieckmann K
Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel.
Trans. Royal Soc Trop Med &amp; Hyg 2002, 96(6):683-4</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ADMEC - Australian Defence Medical Ethics Committee</ethicname>
      <ethicaddress>CP2-7-066
Department of Defence
Canberra ACT 2600</ethicaddress>
      <ethicapprovaldate>5/11/1998</ethicapprovaldate>
      <hrec>165/98</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nathan Elmes</name>
      <address>Army Malaria Institute 
Gallipoli Barracks
Enoggera 4051</address>
      <phone>61 7 3332 4801</phone>
      <fax>61 7 3332 4800</fax>
      <email>nathan.elmes@defence.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nathan Elmes</name>
      <address>Army Malaria Institute 
Gallipoli Barracks
Enoggera 4051</address>
      <phone>61 7 3332 4801</phone>
      <fax>61 7 3332 4800</fax>
      <email>nathan.elmes@defence.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nathan Elmes</name>
      <address>Army Malaria Institute 
Gallipoli Barracks
Enoggera 4051</address>
      <phone>61 7 3332 4801</phone>
      <fax>61 7 3332 4800</fax>
      <email>nathan.elmes@defence.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>